sorbitol pathway

(redirected from Polyol pathway)
Also found in: Wikipedia.

sor·bi·tol path·way

a pathway responsible for d-fructose formation from sorbitol; increases in activity as the glucose concentration rises in diabetes.
Synonym(s): polyol pathway
References in periodicals archive ?
Aldose reductase inhibitors can block the polyol pathway and have been used to deliberate the development of diabetic cardiovascular autonomic neuropathy (DCAN).
The all important pericyte loss in DR is discussed in the next chapter, the polyol pathway, the role of the pericyte in maintaining functional and structural integrity is well written.
Some of the key pathways involved in diabetic nephropathy include the polyol pathway, activation of protein kinase C, generation of advanced glycation products, activation of cytokines and generation of reactive oxygen species.
Researchers have shown that both enzymes of the polyol pathway contributed to hyperglycemia-induced oxidative stress in the lens, and likely cause neuronal dysfunction as well.
14) Oxidative stress, AGE accumulation, and the polyol pathway are all implicated in diabetic neuropathy.
19) In addition, studies have shown that type 2 diabetics with diabetic retinopathy have increased activity of aldose reductase and sorbitol levels compared with type 2 diabetics without retinopathy, indicating increased polyol pathway activation in the pathology of diabetic retinopathy.
21) Researchers have also shown that hyperglycemia is associated with adverse effects on the brain polyol pathway activity, neuronal structural changes, and impaired long-term spatial memory.
The enzymes aldose reductase and sorbitol dehydrogenase play key roles in the polyol pathway (Winegrad, 1987).
Aldose reductase and the role of the polyol pathway in diabetic nephropathy.
Red blood cell sorbitol as an indicator of polyol pathway activity.
Aldose reductase (AR) catalyzes glucose to sorbitol, and then sorbitol dehydrogenase converts sorbitol to fructose in the polyol pathway of glucose metabolism.
Continuous inhibition of excessive polyol pathway flux in peripheral nerves by aldose reductase inhibitor fidarestat leads to improvement of diabetic neuropathy.